MED9

Across TCGA pan-cancer cohorts, MED9 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated MED9 data layer compared with 26 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher MED9 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MED9 expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

HNSC, LSCC, and LUAD are the cancer types where MED9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.303	0.886	.007	43	view →
LSCC	OS	Median	All	0.926	0.710	<.001	31	view →
LUAD	DFS	Quartile	All	0.933	0.352	.002	11	view →
PDAC	OS	Quartile	III,IV	0.440	0.977	.013	9	view →
CCRCC	DFS	Median	All	1.000	0.337	.022	8	view →
UCEC	DFS	Quartile	All	1.000	0.911	.041	2	view →
GBM	OS	Quartile	All	0.607	0.915	.023	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

MED9–HNSC (DFS)

Open the HNSC breakdown →